



June 24, 2026

Company Name:	GNI Group Ltd.
Representative:	Director, Representative Executive Officer, President and CEO Ying Luo, PhD (Security Code: 2160, TSE Growth)
Contact Person:	Director, Executive Officer Ping Zhang (TEL. 03-6214-3600)

Notice Concerning Filing of Form S-3 Registration Statement by Gyre Therapeutics

(Note) This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the Japanese original shall prevail.

GNI Group Ltd. (the “Company”) announces that its consolidated subsidiary, Gyre Therapeutics, Inc. (“Gyre”), has filed a registration statement on Form S-3 with the U.S. Securities and Exchange Commission.

This filing is a registration procedure under the U.S. Securities Act in connection with Gyre’s acquisition of Cullgen Inc. (“Cullgen”) as a wholly owned subsidiary, which was announced on May 7, 2026. The registration statement relates to shares of Gyre common stock issued to Cullgen stockholders as consideration for the acquisition, in order to enable the future sale of such shares by those stockholders. Accordingly, this filing is not intended to raise new capital for Gyre.

The Company’s current effective ownership interest in Gyre is approximately 70%, and there is no change in the Company’s policy regarding its ownership of Gyre shares as a result of this filing. The Company does not expect this filing to have any material impact on its consolidated financial results.

[For Reference]

S-3 published by Gyre Therapeutics, Inc. on June 23, 2026

[0001140361-26-025999 | S-3 | Gyre Therapeutics, Inc](#)